The recent launch of a state-of-the-art beta-lactam injectable facility enhances the company’s capabilities, reinforcing its commitment to quality and innovation ... .
XACDURO, a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, was approved in May 2023 for treating hospital-acquired bacterial pneumonia and ...
"Community-Acquired Bacterial PneumoniaMarket" ... Treatment primarily involves antibiotic therapy, with macrolides, fluoroquinolones, and beta-lactam antibiotics being commonly prescribed based on bacterial resistance patterns and disease severity ... 1 ... 2.